Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.45
AHRO's Cash to Debt is ranked higher than
64% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. AHRO: 1.45 )
AHRO' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 1.45

F-Score: 2
Z-Score: -191.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -2529.13
AHRO's ROA (%) is ranked lower than
59% of the 748 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. AHRO: -2529.13 )
AHRO' s 10-Year ROA (%) Range
Min: -11733.33   Max: 673.46
Current: -2529.13

-11733.33
673.46
ROC (Joel Greenblatt) (%) -103057.14
AHRO's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. AHRO: -103057.14 )
AHRO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -103057.14   Max: -4500
Current: -103057.14

-103057.14
-4500
EBITDA Growth (%) -35.70
AHRO's EBITDA Growth (%) is ranked lower than
52% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. AHRO: -35.70 )
AHRO' s 10-Year EBITDA Growth (%) Range
Min: -96.3   Max: 284.9
Current: -35.7

-96.3
284.9
EPS Growth (%) -34.40
AHRO's EPS Growth (%) is ranked higher than
52% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. AHRO: -34.40 )
AHRO' s 10-Year EPS Growth (%) Range
Min: -96.5   Max: 341.4
Current: -34.4

-96.5
341.4
» AHRO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AHRO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -1.18
AHRO's EV-to-EBIT is ranked lower than
53% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. AHRO: -1.18 )
AHRO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.18

Current Ratio 0.20
AHRO's Current Ratio is ranked lower than
59% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. AHRO: 0.20 )
AHRO' s 10-Year Current Ratio Range
Min: 0.01   Max: 4.31
Current: 0.2

0.01
4.31
Quick Ratio 0.20
AHRO's Quick Ratio is ranked lower than
59% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. AHRO: 0.20 )
AHRO' s 10-Year Quick Ratio Range
Min: 0.01   Max: 4.31
Current: 0.2

0.01
4.31

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -24.47
AHRO's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. AHRO: -24.47 )
AHRO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -24.47

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
AtheroNova, Inc. was incorporated in Delaware in 1997. The Company, through AtheroNova operations, engages in the development of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds principally for the treatment of atherosclerosis, which is the primary cause of cardiovascular diseases. As of December 31, 2012, it has not generated any revenues from the development of interllectual property and is therefore a development stage company.
» More Articles for AHRO

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 Jul 30 2014
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 Jul 30 2014
AtheroNova Announces Pre-IND Filing Under Section 505(b)(2) Jul 15 2014
AtheroNova Announces Pre-IND Filing Under Section 505(b)(2) Jul 15 2014
ATHERONOVA INC. Financials May 29 2014
AtheroNova Announces Russian Ministry of Healthcare Approval for Initiation of Phase 1b Trial... May 28 2014
ATHERONOVA INC. Files SEC form 8-K, Unregistered Sale of Equity Securities May 16 2014
AtheroNova Announces 2013 Financial Results Mar 06 2014
AtheroNova Announces Preliminary Positive Phase 1 Clinical Data From Lead Drug AHRO-001, a Potential... Feb 27 2014
SeeThruEquity Initiates Research Coverage on AtheroNova, Inc. Jan 09 2014
AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for... Dec 05 2013
AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for... Dec 05 2013
AtheroNova: Undervalued, Underappreciated, And Underestimated Nov 14 2013
Atherosclerosis Researcher Dr. Erik Stroes Joins AtheroNova's Clinical Advisory Board Oct 15 2013
AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas Sep 19 2013
AtheroNova Inc. Presenting at 15th Annual Rodman & Renshaw Investment Conference Sep 04 2013
Medical Marijuana, Biotech and Precious Metals Micro-Caps Under the Radar Aug 27 2013
Here’s How Russia Is Helping Grow the Biotech Sector Aug 17 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide